Serum gamma glutamyl-transferase is a sensitive but unspecific marker of metastatic renal cell carcinoma
Serum gamma glutamyl-transferase is a sensitive but unspecific marker of metastatic renal cell carcinoma
复制标题
DOI：
10.1111/j.1442-2042.2006.01719.x
复制
发表时间：
2007-04-01
影响因子：
2.6
通讯作者：
Mimic-Oka, Jasmina
中科院分区：
文献类型：
--
作者：
Simic, Tatjana;Dragicevic, Dejan;Mimic-Oka, Jasmina
目标：目的探讨血清γ-谷氨酰转移酶（GGT）作为肾癌转移标志物的作用。方法：对156例局限性肾癌患者和60例经超声、CT和骨扫描证实的转移性肾癌患者进行血清碱性磷酸酶（ALP）和GGT测定。对照组为50例性别、年龄相匹配的健康志愿者。比较了两种酶作为转移性疾病标志物的敏感性和特异性。在转移性患者中，酶活性进行了分析，根据网站的transferation.Results：碱性磷酸酶和GGT活性是正常的，在大多数局限性肾细胞癌患者和增加，在大多数转移性疾病的患者（80%和70%，分别）。GGT与碱性磷酸酶在敏感性（70% vs 80%）和特异性（89% vs 92%）方面无显著差异。关于转移部位，仅肝脏转移的患者中GGT和碱性磷酸酶升高的频率较高（分别为80%和90%）。所有肝和骨转移的患者都表现出两种酶的活性增加。尽管骨细胞不表达GGT的事实，增加的活动被发现在骨肿瘤的患者只有（45%），这表明酶可能被释放从肿瘤cell.Conclusions：我们的数据提供的证据表明，GGT是一个敏感的标志物转移性肾细胞癌。然而，异常GGT活性的结果不能指定参与的网站。
Objective: To address the role of serum gamma-glutamyl transferase (GGT) as a marker of metastases in patients with renal cell carcinoma.Methods: Serum alkaline phosphatase and GGT were determined in 156 patients with localized renal cell carcinoma and 60 patients with metastases as proven by echosonography, computerized tomography and bone scan. The control group consisted of 50 healthy subjects matched for sex and age. Sensitivity and specificity of both enzymes as markers of metastatic disease were compared. In metastatic patients, enzyme activities were analyzed according to the site of metastases.Results: Both alkaline phosphatase and GGT activities were normal in majority of patients with localized renal cell carcinoma and increased in most of the patients with metastatic disease (80% and 70%, respectively). GGT did not significantly differ from alkaline phosphatase in terms of sensitivity (70% vs 80%) and specificity (89% vs 92%). Concerning the site of metastases, high frequencies of increased GGT and alkaline phosphatase were found in patients with liver-only metastases (80% and 90%, respectively). All of the patients with both liver and bone metastases exhibited increased activity of both enzymes. Despite the fact that bone cells do not express GGT, increased activity was found in patients with bone metastases-only (45%), suggesting that enzymes might be released from tumor cells.Conclusions: Our data provided evidence that GGT is a sensitive marker of metastatic renal cell carcinoma. However, findings of abnormal GGT activity cannot specify the site of involvement.